Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499359 | 0.92 | CHRM4 (0.45) | CHRM4KDM4ELTA4HMAOA | |
| SCHEMBL5563921 | 0.89 | CHRNA7 (0.42) | CHRM4 | |
| SCHEMBL5563315 | 0.89 | CHRM4 (0.41) | CHRM4 | |
| SCHEMBL5568456 | 0.88 | HTR2A (0.42) | KDM4EALDH1A1 | |
| SCHEMBL5567916 | 0.88 | CHRM4 (0.44) | CHRM4 | |
| SCHEMBL6295115 | 0.84 | CHRM4 (0.40) | CHRM4 | |
| SCHEMBL6300947 | 0.81 | DRD2 (0.42) | CHRM4KDM4E | |
| SCHEMBL5569687 | 0.81 | CARM1 (0.50) | — | |
| SCHEMBL5569587 | 0.80 | CHRNA7 (0.49) | KDM4EALDH1A1 | |
| SCHEMBL5563582 | 0.79 | CARM1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266896-B1 | Linear or cyclic ureas, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-17 | — | — | EP | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| EP-1266896-A1 | Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | CHRM4 929/4885KDM4E 3562/4885ALDH1A1 424/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | CHRM4 1108/4885KDM4E 3317/4885ALDH1A1 367/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | CHRM4 1108/4885KDM4E 3317/4885ALDH1A1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.